Apollomics Inc. APLM
Annual
Quarterly
FY2024 · ended Dec 31, 2024 · Revenue $0 · Filed Apr 3, 2025
Apollomics Inc. (APLM) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2024, which ended Dec 31, 2024, it reported revenue of $0 and a net loss of $53.9 million. Free cash flow was -$28.8 million. As of Dec 31, 2024 it held $9.8 million in cash and investments and $966,000 in total debt.
Revenue
$0
Net income
$-53.86M
+68.8% vs prior year
Operating cash flow
$-28.74M
+33.5% vs prior year
Free cash flow
$-28.77M
+33.4% vs prior year
EPS
$-52.80
+77.2% vs prior year
Dividend per share
None
Shares outstanding
2.20M
+99.0% vs prior year
Net cash
$8.80M
FY 2024
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- APLM (Nasdaq), APLMW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Cayman Islands
- Headquarters
- Covina, CA
- SEC filer status
- Non-accelerated filer, Emerging growth company
- SEC CIK
- 1944885
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Operating income | — | — | $976,000 |
| Net income | -$53.9M | -$172.6M | -$240.8M |
| Diluted EPS | -$52.80 | -$231.99 | -$844.95 |
| Operating cash flow | -$28.7M | -$43.2M | -$42.8M |
| Free cash flow | -$28.8M | -$43.2M | -$43.2M |
| Total assets | $13.1M | $55.4M | $76.5M |
| Total liabilities | — | — | $448.1M |
| Stockholders' equity | $4.9M | $41.2M | -$448.1M |
| Cash and investments | $9.8M | $32.1M | $32.7M |
| Total debt | $966,000 | $4.7M | $991,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Aug 12, 2026 | Aug 11, 2026 |
| 6-K | Current report (foreign issuer) | Jul 21, 2026 | Jul 21, 2026 |
| 6-K | Current report (foreign issuer) | Jul 14, 2026 | Jul 14, 2026 |
| 6-K | Current report (foreign issuer) | Jun 24, 2026 | Jun 24, 2026 |
| 6-K | Current report (foreign issuer) | Apr 27, 2026 | Apr 27, 2026 |
| 20-F | Annual report (foreign issuer) | Apr 24, 2026 | Dec 31, 2025 |
All 183 Apollomics Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.